贝伐珠单抗联合化疗治疗晚期胃癌的Meta分析

兰州大学机构库 >第一临床医学院

	贝伐珠单抗联合化疗治疗晚期胃癌的Meta分析
Alternative Title	Efficacy and safety of bevacizumab combined with chemotherapy for patients with advanced gastric cancer: A Meta-analysis
	孙嘉琦
Subtype	硕士
Thesis Advisor	关泉林
	2016-05-25
Degree Grantor	兰州大学
Place of Conferral	兰州
Degree Name	硕士
Keyword	胃肿瘤贝伐珠单抗 Meta分析
Abstract	目的：采用Meta分析评估贝伐珠单抗联合化疗治疗晚期胃癌的有效性及安全性。方法：计算机检索PubMed、Embase、Cochrane Library、中国期刊全文数据库、维普中文科技期刊数据库和万方数据库等，收集国内外公开发表的有关贝伐珠单抗联合化疗治疗晚期胃癌的相关研究。由2名研究者按照纳入与排除标准独立进行文献筛选、资料提取及文献质量评价后，采用RevMan 5.3软件进行Meta分析。结果：共纳入5项随机对照试验（randomized control trial，RCT），共计1202例晚期胃癌患者。Meta分析结果显示，贝伐珠单抗联合化疗组与单纯化疗组相比，完全缓解[比值比（odds ratio，OR）为2.17，95%可信区间（confidence interval，CI）为1.07～4.38，P＝0.03]、部分缓解（OR为1.53，95%CI为1.19～1.97，P=0.001）和有效率（OR为2.03，95%CI为1.25～3.28，P=0.004）的差异有统计学意义，而1年生存率（OR为1.25，95%CI为0.99～1.58，P=0.06）的差异无统计学意义。在不良反应方面，贝伐珠单抗联合化疗组与单纯化疗组相比，高血压（OR为7.29，95%CI为2.71～19.64，P＜0.0001）和胃肠道穿孔（OR为7.07，95%CI为1.27～39.33，P=0.03）发生率的差异有统计学意义，而骨髓抑制、胃肠道反应、肝功能受损、动静脉血栓栓塞及出血事件发生率的差异均无统计学意义。结论：贝伐珠单抗联合化疗治疗晚期胃癌患者可提高治疗有效率，但该方案可能增加高血压和胃肠道穿孔发生率。
Other Abstract	Objective: The aim of this study was to evaluate the efficacy and safety of bevacizumab combined with chemotherapy for patients with advanced gastric cancer. Methods: Two researchers searched PubMed, Embase, Cochrane Library, Chinese Journal Full-text Database, VIP Chinese Science & Technology Journal Database and Wanfang database, and collected domestic and abroad published research literature about bevacizumab combined with chemotherapy in treatment of advanced gastric cancer. Two reviewers independently screened studies according to the inclusion and exclusion criteria, extracted data and assessed quality of the included studies. Then Meta-analysis was conducted using RevMan 5.3 software. Results: Five randomized control trials involving 1202 patients were included. The Meta-analysis showed that there were statistical significances between bevacizumab combined with chemotherapy group and chemotherapy alone group in complete remission [odds ratio (OR)=2.17, 95% confidence interval (CI)：1.07-4.38, P=0.03], partial remission (OR=1.53, 95%CI: 1.19-1.97, P=0.001) and response rate (OR=2.03, 95%CI: 1.25-3.28, P=0.004). While there was no statistical difference in one-year survival rate (OR=1.25, 95%CI: 0.99-1.58, P=0.06). In terms of adverse reactions, there were statistical significances between bevacizumab combined with chemotherapy group and chemotherapy alone group in the incidence of hypertension (OR=7.29, 95%CI: 2.71-19.64, P<0.0001) and gastrointestinal perforation (OR=7.07, 95%CI: 1.27-39.33, P=0.03), and toxicities were not significantly different between two groups for myelosuppression, gastrointestinal reactions, impaired liver function, arterio-venous thromboembolism and hemorrhage. Conclusions: Bevacizumab combined with chemotherapy in the treatment of patients with advanced gastric cancer can improve the response rate, but the scheme may increase the incidence of hypertension and gastrointestinal perforation.
URL	查看原文
Language	中文
Document Type	学位论文
Identifier	https://ir.lzu.edu.cn/handle/262010/201287
Collection	第一临床医学院
Recommended Citation GB/T 7714	孙嘉琦. 贝伐珠单抗联合化疗治疗晚期胃癌的Meta分析[D]. 兰州. 兰州大学,2016.

Files in This Item:
There are no files associated with this item.

If you have any objections to this item, please fill out the form below and the administrator will contact you as soon as possible.
Content:
Email：	*
Institution:
Verification Code:	Refresh

Any comments and suggestions are welcomed.
Title:	*
Content:
Email：	*
Verification Code:	Refresh

第一临床医学院知识库